 Home > Medical News > Latest Medical News > Yiling Pharmaceutical's Aniprofen Injection Formally Started Phase III Clinical Trial

Yiling Pharmaceutical's Aniprofen Injection Formally Started Phase III Clinical Trial

 Last Update: 2021-04-18
 Source: Internet
 Author: User

Tags

pdr drug reference

phase change memory

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 13, Yiling Pharmaceutical issued an announcement that the company's Phase III clinical trial plan for the company's 1.

It is reported that Aniprofen injection is a non-steroidal analgesic and is intended to be used for postoperative, various cancer pain, trauma, low back pain (acute phase, chronic exacerbation phase), gout attacks, neuralgia, kidney and urinary stones Pain etc.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.